ClinicalTrials.Veeva

Menu
M

Manhattan Behavioral Medicine | New York, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rapastinel
Cariprazine
Pimavanserin
Aticaprant
SPD489
Vilazodone
Vortioxetine
Levomilnacipran
AVP-786
ATH-1017

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 50 total trials
Locations recently updated

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

Enrolling
Schizophrenia
Drug: Cariprazine
Drug: Placebo

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Active, not recruiting
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Di...

Active, not recruiting
Alzheimer's Disease
Drug: BPN14770
Drug: Placebo

Trial sponsors

Otsuka logo
Allergan logo
Forest Laboratories logo
AbbVie logo
Acadia Pharmaceuticals logo
Athira Pharma logo
Biohaven logo
Janssen (J&J Innovative Medicine) logo
Karuna Therapeutics logo
Shire logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems